Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Melissa Hardesty, MD, MPH
Advertisement
Articles by Melissa Hardesty, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
4
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
5
